Fmoc-Phg-OHCAS# 102410-65-1 |
- PF-4708671
Catalog No.:BCC5031
CAS No.:1255517-76-0
- BIX 02565
Catalog No.:BCC4303
CAS No.:1311367-27-7
- BI-D1870
Catalog No.:BCC5030
CAS No.:501437-28-1
- CMK
Catalog No.:BCC1489
CAS No.:821794-90-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 102410-65-1 | SDF | Download SDF |
| PubChem ID | 7269367 | Appearance | Powder |
| Formula | C23H19NO4 | M.Wt | 373.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-phenylacetic acid | ||
| SMILES | C1=CC=C(C=C1)C(C(=O)O)NC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24 | ||
| Standard InChIKey | PCJHOCNJLMFYCV-NRFANRHFSA-N | ||
| Standard InChI | InChI=1S/C23H19NO4/c25-22(26)21(15-8-2-1-3-9-15)24-23(27)28-14-20-18-12-6-4-10-16(18)17-11-5-7-13-19(17)20/h1-13,20-21H,14H2,(H,24,27)(H,25,26)/t21-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Fmoc-Phg-OH Dilution Calculator
Fmoc-Phg-OH Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6781 mL | 13.3905 mL | 26.7809 mL | 53.5619 mL | 66.9523 mL |
| 5 mM | 0.5356 mL | 2.6781 mL | 5.3562 mL | 10.7124 mL | 13.3905 mL |
| 10 mM | 0.2678 mL | 1.339 mL | 2.6781 mL | 5.3562 mL | 6.6952 mL |
| 50 mM | 0.0536 mL | 0.2678 mL | 0.5356 mL | 1.0712 mL | 1.339 mL |
| 100 mM | 0.0268 mL | 0.1339 mL | 0.2678 mL | 0.5356 mL | 0.6695 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Fmoc-Phg-OH
- Jasplakinolide
Catalog No.:BCC7485
CAS No.:102396-24-7
- AF-DX 116
Catalog No.:BCC6939
CAS No.:102394-31-0
- Glyburide
Catalog No.:BCC4784
CAS No.:10238-21-8
- Negsehisandrin G
Catalog No.:BCN2674
CAS No.:1023744-69-5
- Naringin
Catalog No.:BCN6312
CAS No.:10236-47-2
- Cadensin D
Catalog No.:BCN7260
CAS No.:102349-35-9
- (R)-Eriodictyol-8-C-beta-D-glucopyranoside
Catalog No.:BCN8028
CAS No.:1023271-51-3
- Epoxyparvinolide
Catalog No.:BCN5838
CAS No.:102227-61-2
- SGX-523
Catalog No.:BCC1055
CAS No.:1022150-57-7
- Btk inhibitor 1 R enantiomer
Catalog No.:BCC5125
CAS No.:1022150-12-4
- ARN2966
Catalog No.:BCC8074
CAS No.:102212-26-0
- Tyrosine kinase inhibitor
Catalog No.:BCC2020
CAS No.:1021950-26-4
- RN 1747
Catalog No.:BCC7769
CAS No.:1024448-59-6
- Kushenol N
Catalog No.:BCN2984
CAS No.:102490-65-3
- GK921
Catalog No.:BCC8057
CAS No.:1025015-40-0
- Periglaucine A
Catalog No.:BCN5839
CAS No.:1025023-04-4
- Periglaucine B
Catalog No.:BCN7053
CAS No.:1025023-05-5
- SGI-1776 free base
Catalog No.:BCC2232
CAS No.:1025065-69-3
- (-)-Huperzine A
Catalog No.:BCN1057
CAS No.:102518-79-6
- 2,3,23-Trihydroxy-12-oleanen-28-oic acid
Catalog No.:BCN1638
CAS No.:102519-34-6
- R788 disodium
Catalog No.:BCC3695
CAS No.:1025687-58-4
- Methyl lucidente G
Catalog No.:BCN8269
CAS No.:102607-20-5
- Ganoderic acid L
Catalog No.:BCN8204
CAS No.:102607-24-9
- Saprorthoquinone
Catalog No.:BCN3147
CAS No.:102607-41-0
Racemisation of N-Fmoc phenylglycine under mild microwave-SPPS and conventional stepwise SPPS conditions: attempts to develop strategies for overcoming this.[Pubmed:22451378]
J Pept Sci. 2012 May;18(5):302-11.
We have been engaged in the microwave-solid phase peptide synthesis (SPPS) synthesis of the phenylglycine (Phg)-containing pentapeptide H-Ala-Val-Pro-Phg-Tyr-NH(2) (1) previously demonstrated to bind to the so-called BIR3 domain of the anti-apoptotic protein XIAP. Analysis of the target peptide by a combination of RP-HPLC, ESI-MS, and NMR revealed the presence of two diastereoisomers arising out of the racemisation of the Phg residue, with the percentage of the LLLDL component assessed as 49%. We performed the synthesis of peptide (1) using different microwave and conventional stepwise SPPS conditions in attempts to reduce the level of racemisation of the Phg residue and to determine at which part of the synthetic cycle the epimerization had occurred. We determined that racemisation occurred mainly during the Fmoc-group removal and, to a much lesser extent, during activation/coupling of the Fmoc-Phg-OH residue. We were able to obtain the desired peptide with a 71% diastereomeric purity (29% LLLDL as impurity) by utilizing microwave-assisted SPPS at 50 degrees C and power 22 Watts, when the triazine-derived coupling reagent DMTMM-BF(4) was used, together with NMM as an activator base, for the incorporation of this residue and 20% piperidine as an Fmoc-deprotection base. In contrast, the phenylalanine analogue of the above peptide, H-Ala-Val-Pro-Phe-Tyr-NH(2) (2), was always obtained as a single diastereoisomer by using a range of standard coupling and deprotection conditions. Our findings suggest that the racemisation of Fmoc-Phg-OH, under both microwave-SPPS and stepwise conventional SPPS syntheses conditions, is very facile but can be limited through the use of the above stated conditions.
